Agilus Diagnostics will integrate Lucence’s advanced molecular testing solutions into its comprehensive oncology diagnostics portfolio

Agilus Diagnostics and Lucence, a pioneering molecular diagnostics company, have entered into a strategic collaboration to advance cancer diagnostics and personalised medicine in India. The collaboration will integrate Lucence’s cutting-edge molecular testing technologies into Agilus’ extensive laboratory network, offering enhanced cancer detection, treatment selection, and monitoring capabilities.

Through this collaboration, Agilus Diagnostics will integrate Lucence’s advanced molecular testing solutions into its comprehensive oncology diagnostics portfolio. LiquidHALLMARK is an ultra-sensitive, next-generation sequencing liquid biopsy that analyses circulating tumour DNA (ctDNA) and circulating tumour RNA (ctRNA) for clinically relevant biomarkers across various cancers. LiquidHALLMARK profiles actionable somatic mutations in 80 ctDNA genes and 37 ctRNA fusions.

"Our collaboration with Lucence strengthens our ability to provide world-class cancer diagnostics, offering oncologists and patients access to precision-driven solutions," said Dr Anand K, MD and CEO, Agilus Diagnostics.

Lucence’s proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities, offering liquid biopsy-based screening for early cancer detection, recurrence monitoring, and therapy personalisation. By integrating these pioneering tests into its an extensive network of laboratories, Agilus Diagnostics aims to enhance the accessibility of precision oncology across India.

“Lucence is dedicated to transforming cancer care with non-invasive, highly accurate genomic tests. This collaboration with Agilus Diagnostics allows us to scale our impact and bring the benefits of precision oncology to a larger patient population in India,” said Tan Min-Han, Founding CEO and Medical Director, Lucence.